Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Return on Assets were -127.60%. At the close of the day, the stock reported a Market Cap of $100.92M in the Biotechnology Industry.
The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.
Recently, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that it will present preliminary data from the Phase IIa study of RX-3117 in advanced and metastatic bladder cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, which is being held June 2-6 in Chicago, Illinois.
The company traded a total volume of 2,269,056, and the stock saw a change of 7.30% in the previous trading session. The company reported a 52-Week High of $4.46% and a52-Week Low of $3254.33%. The monthly Volatility of Rexahn Pharmaceuticals, Inc. stood at 12.54%.
Rexahn Pharmaceuticals, Inc. announced EPS of $-1.14. This represents a growth of 45.70% in EPS this year compared to what was reported last financial year and represents an overall growth of 18.90% over the past five year.
Rexahn Pharmaceuticals, Inc.’s ownership was spread out with Insider Ownership amounting to 2.40% while Institutional Ownership amounted to 9.00%. Total insider transactions was -30.54% and total Institutional Transactions was 1.04%.
Return on Assets reported was -127.60%. Return on Equity for the financial year was -209.00%. Current and quick ratio amounted to 11.30 and 11.30 respectively.
The company has 23.69M shares outstanding at a price of $4.26 per share.
Rexahn Pharmaceuticals, Inc. RNN has announced a Dividend Yield of 30.05%. EPS growth reported for this year was 45.70%. For the past five years, the company has reported EPS growth of 18.90% with EPS growth for the next year projected to be -16.90%.